Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
Equipping Healthcare Professionals with the Necessary Tools for Improving Care in Ovarian Cancer
Choose from the criteria below to find an activity that fits you best.
View the other Modules in this CSPE Core Curriculum Series:
Fertility Module #1: Fertility Care Considerations: Introduction to Infertility
Fertility Module #3: Infertility: Protocols and Patient Management
Fertility Module #4: Fertility Care Considerations: Special Populations and Considerations
|This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.|
A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities
Infertility is a disease of the reproductive system. It is defined for most couples as not being able to get pregnant or maintain a pregnancy despite having frequent, unprotected, appropriately timed intercourse for at least a year. It is estimated that during their primary reproductive years, that 10 to 15 percent of couples in the United States are infertile. This condition affects both women and men. It is believed that almost 7 million women and 4 million men are affected by infertility.
Module 2 will review the mechanism of action of the typical agents used to affect infertility. Medication adverse effects, administration, storage, and other information regarding these agents will also be discussed.
The target audience for this activity includes pharmacists and nurses.
Upon completion of this activity, participants will be able to:
Ann Scalia, BSN, RN, CNOR
Director, Clinical Education
AllianceRx Walgreens Prime
Nancy Harrington, RNC-REIN
Senior Specialist Clinical Education
AllianceRx Walgreens Prime
Release Date: September 1, 2021
Expiration Date: September 1, 2024
ACPE Credit Designation (Pharmacist CE)
This CE activity is jointly provided by ProCE, LLC and the National Association
of Specialty Pharmacy (NASP). ProCE, LLC is accredited by the Accreditation Council
for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal
Activity Number 0221-9999-21-226-H01-P has been assigned to this home study knowledge-based
activity. This activity is approved for 1.25 contact hour (0.125 CEU) in states that
recognize ACPE providers. Completion of an evaluation and post-test with a score
of 70% or higher is required to receive CE credit. Proof of completion will be posted
in NABP CPE Monitor profiles. No partial credit will be given.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented
by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is
jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME),
the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing
Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity
is 1.25 contact hours.
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed during their presentation.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty and planners reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
CCO and ProCE Staff have no relevant conflicts of interest to report.
Jean Cherry does not have any relevant conflicts of interest to report.
Nancy Harrington, RN, RNC-REIN does not have any relevant conflicts of interest to report.
Ann Scalia, BSN, RN, CNOR does not have any relevant conflicts of interest to report.
Potential conflicts of interest were resolved with a peer review process provided by Jean Cherry, BSN, MBA.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is self-funded by NASP.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.